Suppr超能文献

一种用于同时检测单个循环肿瘤细胞(CTC)中热点突变的多标记液滴芯片检测方法的开发与验证。

Development and validation of a multi-marker liquid bead array assay for the simultaneous detection of and hotspot mutations in single circulating tumor cells (CTCs).

作者信息

Stergiopoulou Dimitra, Georgoulias Vassilis, Markou Athina, Lianidou Evi

机构信息

Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.

First Department of Medical Oncology, METROPOLITAN General Hospital, 264, Mesogion Av, Cholargos, Athens, Greece.

出版信息

Heliyon. 2024 Sep 12;10(19):e37873. doi: 10.1016/j.heliyon.2024.e37873. eCollection 2024 Oct 15.

Abstract

BACKGROUND

and mutations are associated with progression and therapy resistance in metastatic breast cancer (MBC). CTCs are highly heterogeneous and their analysis at single cell level can provide unique information for mutational profiling and the existence of different sub-clones related to tumor progression. We have developed a novel multi-marker liquid bead array assay based on combination of an enzymatic mutation enrichment method, multiplex PCR-based assay, and liquid bead array technology for the simultaneous detection of and hotspot mutations in liquid biopsy samples. We focus on single CTCs, however the assay can be used for bulk CTC and ctDNA analysis.

MATERIALS AND METHODS

Single CTCs were isolated from an ER+/HER2+ MBC patient from CellSearch® cartridges using the VyCAP Puncher System and subjected to whole genome amplification followed by nuclease-assisted minor-allele enrichment with probe-overlap (NaME-PrO) enrichment. The assay was validated for analytical sensitivity and specificity for the simultaneous detection of () and (Y537S) mutations in single CTCs, while its clinical performance was evaluated on 22 single CTCs and three single white blood cells (WBCs).

RESULTS

The developed multi-marker liquid bead array assay is novel, highly specific and sensitive for both mutation panels. The assay can reliably detect mutation-allelic-frequencies (MAFs) as low as 0.1 %. The presence of and mutations was detected in 13.6 % and 72.7 % of single CTCs, respectively. The developed assay is sample-saving since it requires only 2 μL of amplified DNA to check for nine hotspot and mutations in a single cell. The developed liquid bead array assay (Luminex, US), based on a 96 microwell plate format, enables the simultaneous analysis of 96 single cells.

CONCLUSIONS

The developed novel multi-marker liquid bead array assay for the simultaneous detection of and hotspot mutations in single CTCs is highly specific, highly sensitive, high-throughput, and sample-, cost-, and time-saving. This multi-marker liquid bead array assay can be extended to detect up to 100 mutations in many genes at once and can be applied for bulk CTC and ctDNA analysis.

摘要

背景

和 突变与转移性乳腺癌(MBC)的进展及治疗耐药性相关。循环肿瘤细胞(CTC)高度异质性,在单细胞水平对其进行分析可为突变谱分析以及与肿瘤进展相关的不同亚克隆的存在提供独特信息。我们基于酶促突变富集方法、多重聚合酶链反应(PCR)检测法和液滴微珠阵列技术的组合,开发了一种新型多标记液滴微珠阵列检测法,用于同时检测液体活检样本中的 和 热点突变。我们专注于单个CTC,但该检测法也可用于大量CTC和循环肿瘤DNA(ctDNA)分析。

材料与方法

使用VyCAP打孔系统从一名雌激素受体阳性/人表皮生长因子受体2阳性(ER+/HER2+)的MBC患者的CellSearch®试剂盒中分离单个CTC,并进行全基因组扩增,随后采用核酸酶辅助的探针重叠微等位基因富集法(NaME-PrO)进行富集。该检测法针对同时检测单个CTC中的 ( )和 (Y537S)突变的分析灵敏度和特异性进行了验证,同时在22个单个CTC和3个单个白细胞(WBC)上评估了其临床性能。

结果

所开发的多标记液滴微珠阵列检测法新颖,对两个突变组均具有高特异性和高灵敏度。该检测法能够可靠地检测低至0.1%的突变等位基因频率(MAF)。在分别13.6%和72.7%的单个CTC中检测到 突变和 突变的存在。所开发的检测法节省样本,因为在单个细胞中检测9个 和 热点突变仅需2 μL扩增DNA。所开发的基于96孔板形式的液滴微珠阵列检测法(美国Luminex公司)能够同时分析96个单细胞。

结论

所开发的用于同时检测单个CTC中 和 热点突变的新型多标记液滴微珠阵列检测法具有高特异性、高灵敏度、高通量,且节省样本、成本和时间。这种多标记液滴微珠阵列检测法可扩展为一次检测多达100个基因中的突变,并可应用于大量CTC和ctDNA分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b4/11462463/e28e82330e3a/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验